Abera Bioscience AB reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported revenue was SEK 2.6 million compared to SEK 0.014 million a year ago. Net loss was SEK 2.42 million compared to SEK 4.53 million a year ago. Basic loss per share from continuing operations was SEK 0.17 compared to SEK 0.38 a year ago. Diluted loss per share from continuing operations was SEK 0.17 compared to SEK 0.38 a year ago.
For the full year, revenue was SEK 2.65 million compared to SEK 1.85 million a year ago. Net loss was SEK 16.72 million compared to SEK 19.38 million a year ago. Basic loss per share from continuing operations was SEK 1.26 compared to SEK 1.66 a year ago. Diluted loss per share from continuing operations was SEK 1.26 compared to SEK 1.66 a year ago.